1. Home
  2. News & Press
  3. Myriad Genetics Announces Upgrades to the GeneSight® Test

Myriad Genetics Announces Upgrades to the GeneSight® Test

Myriad Genetics Announces Upgrades to the GeneSight® Test

With continued commitment to innovation, company makes updates to industry-leading PGx report

SALT LAKE CITY, [March 13, 2022] –Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, announced the GeneSight® Psychotropic test has released a new version, adding three medications and making refinements to the test.

“We have made these enhancements to the GeneSight test based on a comprehensive analysis of peer-reviewed literature and our continued commitment to provide clinicians with genetic insights to help inform treatment decisions,” said Mark Pollack, MD, chief medical officer, Myriad Mental Health. “These updates help ensure the GeneSight test provides an even more complete picture of patients’ potential outcomes with certain medications prescribed to treat depression, anxiety, ADHD, and other psychiatric conditions.”

Three medications have been added to the GeneSight test – suvorexant (Belsomra®), lemborexant (Dayvigo®) and viloxazine (Qelbree®). Suvorexant and lemborexant are included on the Anxiolytics and Hypnotics page of the report, while viloxazine is included in the Non-stimulants section. Other refinements include revised categorization rules for amitriptyline, removal of clinical consideration 4 from paroxetine when variation is present in HTR2A, and revised phenotype language for the HLA genes.

The updated test is available for prescribing clinicians on March 13. If clinicians have previously ordered the test for patients, they may upgrade their report at no cost to the clinician or the patient though the myGeneSight.com portal.

This is the second update of the GeneSight test in the past year. Previously, the test was updated to include stimulants and non-stimulants approved for the treatment of ADHD, and three additional genes – ADRA2A, CES1A1, and COMT (the latter gene was added for informational purposes).

“We constantly are looking for new ways to enhance the clinician/patient experience and relationship, and this latest upgrade to the GeneSight test is proof,” said Jay Elliott, vice president of Medical Affairs, Myriad Mental Health.

About the GeneSight® Test

The GeneSight Psychotropic test from Myriad Genetics is the category-leading pharmacogenomic (PGx) test for 64 medications commonly prescribed for depression, anxiety, ADHD, and other psychiatric conditions. The GeneSight test can help inform clinicians about how a patient’s genes may impact how they metabolize and/or respond to certain psychiatric medications. It has been given to more than 1.5 million patients by tens of thousands of clinicians to provide genetic information that is unique to each patient. The GeneSight test supplements other information considered by a clinician as part of a comprehensive medical assessment. Learn more at GeneSight.com.

About Myriad Genetics

Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and wellbeing for all, empowering individuals with vital genetic insights and enabling healthcare providers to better detect, treat and prevent disease. Myriad discovers and commercializes genetic tests that determine the risk of developing disease, assess the risk of disease progression, and guide treatment decisions across medical specialties where critical genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit the company’s website: www.myriad.com.

Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice CDx, Vectra, EndoPredict, Prequel, Foresight, GeneSight, riskScore and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries.